In summary, these data show that blocking MEK1/2/PLK1 substantially impacts tumor growth in multiple models of basal‐like, triple‐negative breast cancer and represents a novel candidate strategy for treating breast tumors that exhibit high CEP55 expression. This evidence concerns the gene PLK1 and breast neoplasm.